Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 3
2005 4
2006 3
2007 5
2008 7
2009 3
2010 7
2011 3
2012 3
2013 1
2014 3
2015 5
2016 2
2017 2
2018 2
2019 1
2020 1
2021 2
2022 1
2023 1
2024 1
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
O'Donoghue ML, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Ran X, Murphy SA, Wang H, Wu Y, Kassahun H, Sabatine MS; OCEAN(a)-DOSE Trial Investigators. O'Donoghue ML, et al. N Engl J Med. 2022 Nov 17;387(20):1855-1864. doi: 10.1056/NEJMoa2211023. Epub 2022 Nov 6. N Engl J Med. 2022. PMID: 36342163 Free article. Clinical Trial.
Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver. METHODS: We conducted a randomized, double-blind, placebo-controlled, dose-finding trial involving patients with established atherosclerotic cardiovascular disease and a lipoprotein(a) …
Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver. METHODS: We conducted a randomized, double-b …
The pharmacodynamic and clinical trial evidence for statin dose.
Dimmitt SB, Stampfer HG, Warren JB. Dimmitt SB, et al. Br J Clin Pharmacol. 2018 Jun;84(6):1128-1135. doi: 10.1111/bcp.13539. Epub 2018 Apr 16. Br J Clin Pharmacol. 2018. PMID: 29393975 Free PMC article. Review.
For example, myopathy has been shown to increase by up to 29-fold and liver dysfunction by up to nine-fold as statin dose is increased. Doses of up to 40-fold ED50 have been promoted, but above five-fold ED50, for example 10 mg of atorvastatin, there is no randomized contr …
For example, myopathy has been shown to increase by up to 29-fold and liver dysfunction by up to nine-fold as statin dose is increase …
Effect of ezetimibe on cholesterol absorption and lipoprotein composition in diabetes and metabolic syndrome.
Federici M. Federici M. Atheroscler Suppl. 2015 Feb;17:17-22. doi: 10.1016/S1567-5688(15)50005-6. Atheroscler Suppl. 2015. PMID: 25659872 Review.
Ezetimibe exerts multiple favorable effects on the lipoprotein profile and reduces some inflammatory markers. ...Further analysis is needed also to determine whether the stronger effects of ezetimibe seen in patients with diabetes are a consequence of an interaction …
Ezetimibe exerts multiple favorable effects on the lipoprotein profile and reduces some inflammatory markers. ...Further analysis is …
The effect of ezetimibe on NAFLD.
Averna M. Averna M. Atheroscler Suppl. 2015 Feb;17:27-34. doi: 10.1016/S1567-5688(15)50007-X. Atheroscler Suppl. 2015. PMID: 25659874 Review.
NAFLD has become the most common liver disorder in countries, where obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome are common. ...Administration of combination therapy with a statin plus ezetimibe, associated with lifestyle changes, may repr …
NAFLD has become the most common liver disorder in countries, where obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic sy …
Traditional and novel non-statin lipid-lowering drugs.
Jain P. Jain P. Indian Heart J. 2024 Mar;76 Suppl 1(Suppl 1):S38-S43. doi: 10.1016/j.ihj.2023.11.003. Epub 2023 Nov 17. Indian Heart J. 2024. PMID: 37979722 Free PMC article. Review.
The most definite indication of fenofibrate monotherapy is fasting serum triglyceride >500 mg/dl to reduce the risk of acute pancreatitis It offers a modest reduction in cardiovascular events. The statin-ezetimibe combination is commonly used for lipid lowering particul …
The most definite indication of fenofibrate monotherapy is fasting serum triglyceride >500 mg/dl to reduce the risk of acute pancreatitis …
Drug-induced liver disease in 2006.
Arundel C, Lewis JH. Arundel C, et al. Curr Opin Gastroenterol. 2007 May;23(3):244-54. doi: 10.1097/MOG.0b013e3280b17dfb. Curr Opin Gastroenterol. 2007. PMID: 17414839 Review.
The first cases of hepatotoxicity with telithromycin, a new class of ketolide antibiotic, were described along with reports suggesting liver injury from ezetimibe among other agents. The potential for chronic injury to develop after acute drug- …
The first cases of hepatotoxicity with telithromycin, a new class of ketolide antibiotic, were described along with reports suggesting li …
Management of dyslipidaemia in patients with comorbidities-facing the challenge.
Frühwald L, Fasching P, Dobrev D, Kaski JC, Borghi C, Wassmann S, Huber K, Semb AG, Agewall S, Drexel H. Frühwald L, et al. Eur Heart J Cardiovasc Pharmacother. 2025 Mar 13;11(2):164-173. doi: 10.1093/ehjcvp/pvae095. Eur Heart J Cardiovasc Pharmacother. 2025. PMID: 39719399 Review.
Using a literature search of PubMed, we examine the efficacy and safety profiles of various lipid-lowering agents, including statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, fibrates, and icosapent ethyl, focusing particularly on their potential side effects related t …
Using a literature search of PubMed, we examine the efficacy and safety profiles of various lipid-lowering agents, including statins, eze …
Niemann-Pick C1-Like 1 and cholesterol uptake.
Wang LJ, Song BL. Wang LJ, et al. Biochim Biophys Acta. 2012 Jul;1821(7):964-72. doi: 10.1016/j.bbalip.2012.03.004. Epub 2012 Mar 28. Biochim Biophys Acta. 2012. PMID: 22480541 Review.
Consistent with its functions, NPC1L1 distributes on the brush border membrane of enterocytes and the canalicular membrane of hepatocytes in humans. As the molecular target of ezetimibe, a hypocholesterolemic drug, its physiological and pathological significance has …
Consistent with its functions, NPC1L1 distributes on the brush border membrane of enterocytes and the canalicular membrane of hepatocytes in …
59 results